TL;DR
This study reveals significant racial and ethnic disparities in the use of pain and psychiatric medications for advanced-stage colorectal cancer patients nearing the end of life. Black patients were less likely to receive opioids and overall analgesics, while Hispanic patients received more. These disparities persisted even after accounting for socioeconomic factors, highlighting a critical need for equitable, culturally sensitive end-of-life care.
What Problem Does This Paper Address?
Effective symptom management, particularly pain and psychological distress, is crucial for improving the quality of life and even survival for patients with advanced-stage cancer. Colorectal cancer, a leading cause of cancer-related death, is often accompanied by significant pain and psychological burden, especially during the end-of-life (EoL) phase. While racial and ethnic disparities in cancer outcomes are well-documented, there's a significant knowledge gap regarding how these disparities manifest in the use of supportive care medications, specifically analgesics and psychiatric drugs, during the critical EoL period. This paper aims to fill this gap by examining these medication use patterns across different racial and ethnic groups in Medicare beneficiaries with advanced-stage colorectal cancer.
Methods
The researchers conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database from 2005 to 2017. They identified 28,212 patients diagnosed with stage IV colorectal cancer who died within one year of diagnosis.
The core of their analysis involved multivariable logistic regression models to assess differences in medication use by race and ethnicity. They specifically looked at the use of:
- Analgesic medications: categorized into opioid analgesics, non-opioid analgesics, skeletal muscle relaxants, and neuropathic analgesics.
- Psychiatric medications: including antidepressants, anxiolytics, and antipsychotic agents.
Two models were used:
- Model 1: Adjusted for demographic factors (age, sex, marital status), socioeconomic factors (ZIP code-level education and income), clinical factors (residence, year of diagnosis, Charlson comorbidity index), and healthcare utilization (Medicare hospice claims).
- Model 2: Excluded socioeconomic status variables to isolate the independent effect of race and ethnicity, aligning with definitions of healthcare disparities.
Non-Hispanic White patients served as the reference group for all comparisons.
Datasets
The study utilized the SEER-Medicare-linked database (2005-2017). This dataset combines cancer registry data from SEER with Medicare claims data for healthcare services and prescription medication data from Medicare Part D claims. This linkage allows for a comprehensive view of cancer diagnosis, treatment, and medication use in a large, population-based cohort of elderly individuals.
Key Insights and Ideas
- Nuanced Disparities: The study highlights that racial and ethnic disparities in medication use are not monolithic. For instance, while Black patients showed lower opioid and overall analgesic use, Hispanic patients showed higher use of both opioid and non-opioid analgesics. This complexity challenges simple assumptions about undertreatment.
- Psychiatric Medication Gap: A consistent finding across all minority groups was lower utilization of psychiatric medications compared to non-Hispanic White patients. This suggests a broad issue in addressing the psychological distress common in advanced cancer.
- Socioeconomic Factors Matter, But Don't Explain Everything: The persistence of disparities even after adjusting for socioeconomic factors (Model 2) indicates that race and ethnicity play an independent role in access to and utilization of these crucial medications, beyond just income or education levels.
- Neuropathic Pain Paradox: The lack of observed racial differences in neuropathic analgesic use, despite prior research suggesting higher risk in Black patients, is intriguing. It raises questions about whether this reflects similar chemotherapy exposure or potential undertreatment of neuropathy-related pain in minority groups.
- Importance of EoL Care: The study underscores that disparities are particularly concerning during the end-of-life phase, a period where symptom management is paramount for patient comfort and dignity.
Key Results
- Opioid Use: Black patients had significantly lower odds of opioid use (aOR = 0.86) compared to non-Hispanic White patients, while Hispanic patients had higher odds (aOR = 1.12).
- Non-Opioid Analgesics: Hispanic (aOR = 1.22) and Asian (aOR = 1.71) patients had higher use of non-opioid analgesics.
- Skeletal Muscle Relaxants: Asian patients had significantly lower use (aOR = 0.59).
- Overall Analgesic Use: Black patients had lower overall analgesic use (aOR = 0.87), while Hispanic patients had higher use (aOR = 1.15).
- Psychiatric Medications: All minority groups showed consistently lower use of antidepressants, anxiolytics, and overall psychiatric medications compared to non-Hispanic White patients. For example, Black patients had lower odds of antidepressant use (aOR = 0.54) and anxiolytic use (aOR = 0.43).
Limitations and Future Work
The authors acknowledge several limitations:
- Medicare Beneficiary Focus: The study is limited to Medicare beneficiaries (age 65+), so generalizability to younger populations is restricted.
- Inpatient vs. Outpatient: They could not assess inpatient medication use, nonprescription therapies, or non-pharmacologic treatments.
- Maintenance vs. New Prescriptions: The study couldn't distinguish between new psychiatric prescriptions initiated during EoL and maintenance therapy for pre-existing conditions.
- Sociocultural Factors: The analysis did not account for sociocultural or psychosocial factors that might influence medication use.
Future research is needed to:
- Understand Causal Factors: Delve deeper into the reasons behind these disparities, exploring cultural beliefs, stigma, perceived need, provider practices, and access to care.
- Impact on Outcomes: Investigate how these medication use gaps affect patient-reported outcomes like symptom relief and quality of life.
- Develop Strategies: Create and test tailored, culturally responsive interventions to ensure equitable symptom management for all patients, especially those with advanced-stage colorectal cancer.
Summary updated